Latest Royalties News

Rumble Resources has received the second $5 million milestone payment from Elemental Royalty and satisfied a key condition for its ore toll milling agreement, positioning the Western Queen project for pre-development.

Legacy Minerals has locked in a farm-in deal with Aurelia Metals for its Cobar Project, allowing Aurelia to earn up to 90% by funding exploration. This partnership leverages Aurelia's established Cobar Basin operations while Legacy focuses on its flagship Mt Carrington project.

Godolphin Resources has agreed to sell its 49% interest in the Calarie Project to Adavale Resources in a deal structured around shares and long-dated options, aligning with a strategic shift towards its core assets.

Turnstone Resources has exercised its option to acquire the Glava 100 copper-gold permit in Sweden, broadening its critical minerals footprint to seven licences across 100km2. The move sets the stage for drilling in H2 2026, pending regulatory approvals.

Theta Gold Mines has locked in a fully subscribed US$90 million senior secured bond to complete the TGME Gold Mine Project in South Africa, targeting first gold production in early 2027.

Adavale Resources has boosted its Parkes Project gold resource by 44% to 166,000 ounces through a 100% scrip acquisition of the Calarie mining licence and three exploration licences, consolidating its belt-scale position in NSW’s Lachlan Fold Belt.

Venus Metals has sold its 1% Youanmi gold royalty to Franco-Nevada for $46 million, triggering plans for $35 million in special dividends and an in-specie distribution of Rox shares to shareholders.

QEM Limited has pushed back the deadline to complete due diligence on its planned acquisition of two U.S. critical minerals projects, citing legal and environmental concerns that require further investigation.

Vulcan Energy has secured financial close on its €2.2 billion Lionheart Project financing, unlocking funds to advance construction of Europe’s pioneering lithium hydroxide and renewable energy facility in the Upper Rhine Valley.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Classic Minerals has taken a decisive step towards mining at its Forrestania project by issuing a formal Notice of Decision to Commence Mining for the Lady Ada and Lady Magdalene deposits, despite ongoing legal challenges.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.